Regenerative medicine company Orthocell (ASX:OCC) has been granted a Canadian patent for its CelGro collagen medical device platform for soft tissue regeneration and repair applications.
The patent, entitled 'Collagen Scaffold for Cell Growth and a Method for Producing Same', expires in July 2029 and provides additional intellectual property (IP) for the CelGro product platform.
CelGro is a collagen medical device platform for soft tissue regeneration and repair applications. It has been shown to improve tissue in-growth and repair in clinical studies using the collagen medical device to augment repair of the rotator cuff tendon within the shoulder, to guide bone regeneration within the jaw and to assist in the rejoining of severed, or damaged peripheral nerves.
“In line with our strategy, we are focused on building and maintaining patent protection for our leading manufacturing technologies and treatment processes. Securing a divisional patent for CelGro in Canada is another milestone in strengthening our IP position in key global markets. This complements our progression of our products through the registration processes in Australia and internationally.” said Orthocell managing director Paul Anderson.